Status:
COMPLETED
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Vical
Conditions:
Cytomegalovirus Infection
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Objectives of this trial are to: 1. Evaluate the kinetics and magnitude of the CMV-specific immune response post-Towne challenge (3000 pfu) in healthy CMV-seronegative volunteers who received VCL CT0...
Detailed Description
This is a Phase 1, single-center, open-label trial of the live, attenuated Towne CMV vaccine administered as a "challenge" to healthy, CMV-seronegative, adult subjects who previously received the CMV ...
Eligibility Criteria
Inclusion
- 18 to 45 years of age at the time of initial enrollment in trial CT02-ID; normal lab values at study entry; good general health; CMV IgG antibody test \< 4 times last measured value (i.e., at Week 32 after VCL-CT02 administration in CT02-ID was initiated)
- \-
Exclusion
- CMV seropositive; recent vaccination(s); immunodeficiency; vaccination with investigational CMV vaccine(s) other than VCL-CT02 ; pregnant or breast-feeding
- \-
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00370006
Start Date
September 1 2006
End Date
August 1 2007
Last Update
January 11 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.